Date filters select awards with transaction activity in the period. Amounts below are lifetime award obligations. IDV values remain separate.
RTOR BIO-AMT-2312: ASSESSMENT OF THE THERAPEUTIC POTENTIAL OF CHLOROQUINE AND OSELTAMIVIR IN TWO (2) LETHAL MODELS OF INFLUENZA A H5N1Department of Health and Human Services$3.7M obligationsEnds Apr 25, 2028
BIO-AMT-2301: IDIQ CONTRACT MANAGEMENT SUPPORT ACTIVITIESDepartment of Health and Human Services$100.3K obligationsEnds Jul 19, 2027
CHARACTERIZATION OF A NON-PARALYZING BONT-BASED BIOPHARMACEUTICAL FOR THE TREATMENT OF NEUROPATHIC PAINDepartment of Health and Human Services$1.6M obligationsEnds Jun 30, 2027
RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE…Department of Health and Human Services$5.9M obligationsEnds Apr 17, 2027
GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY - TASK AREA A: CORE ADMINISTRATIVE ACTIVITIESDepartment of Health and Human Services$3.6K obligationsEnds Jun 30, 2024
EFFICACY AND SAFETY EVALUATION OF LEAD GENE THERAPY CANDIDATE IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENTDepartment of Health and Human Services$1.9M obligationsEnds Jun 30, 2028
STUDY OF E-CIGARETTE AEROSOL TOXICITY IN IN VIVO NONCLINICAL MODELS.Department of Health and Human Services$38.8M obligationsEnds Jun 30, 2025
TASK ORDER 2 - EXAMINING THE INFLUENCE OF SYNTHETIC COOLING AGENTS ON CIGARETTE SENSORY AND SUBJECTIVE EFFECTS AND USE BEHAVIORDepartment of Health and Human Services$1.3M obligationsEnds Sep 29, 2027
CTP-2022-111127 - SALTSDepartment of Health and Human Services$2.1M obligationsEnds Feb 22, 2027
NON-CLINICAL SAFETY ASSESSMENT OF GENE THERAPY (PCCA, MMAB, DOK7 AND COLQ) TO SUPPORT PLATFORM GENE THERAPY FOR CONGENITAL MYASTHENIC DISEASES (DOK7, COLQ) AND ACIDEMIA (PCCA…Department of Health and Human Services$5.3M obligationsEnds May 31, 2027
EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN METHYL MELANOMIC ACIDEMIA (MMAB) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT.Department of Health and Human Services$452.9K obligationsEnds May 31, 2026
LICENSE AND MAINTENANCE SUPPORT, ON-SITE SUPPORT SERVICES FOR VSP WRAIR.Department of Defense$741.9K obligationsEnds Sep 19, 2026
THE CONTRACTOR SHALL PERFORM THE TRANSFER, VALIDATION AND QUALIFICATION OF BIOANALYTICAL METHODS FOR DETECTION OF CABOTEGRAVIR AND LEVONORGESTREL IN RAT AND NONHUMAN PRIMATE PLASMADepartment of Health and Human Services$680.2K obligationsEnds Apr 15, 2026
GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORYDepartment of Health and Human Services$171.7K obligationsEnds Jun 30, 2024
SOLE SOURCE AWARD OF A 24-MONTH PERIOD, FIRM FIXED PRICE (FFP), ENDS TOXICOLOGICAL STUDIES FOR CENTER FOR TOBACCO PRODUCTS (CTP).Department of Health and Human Services$7.1M obligationsEnds Sep 29, 2027
TRANSFER AND VALIDATION OF BIOANALYTICAL METHOD FOR DETECTION OF CABOTEGRAVIR IN RAT PLASMADepartment of Health and Human Services$255.8K obligationsEnds Jul 31, 2022
GTRP: PHARMACOLOGY/TOXICOLOGY CORE LABORATORY PROJECT FOR RSA NO. 2034Department of Health and Human Services$625.3K obligationsEnds Apr 30, 2023
GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY/TOXICOLOGY CORE LABORATORY - SCIENTIFIC PROJECT FOR RSA NO. 2057 (RADER)Department of Health and Human Services$1.6M obligationsEnds Jun 30, 2024
GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORYDepartment of Health and Human Services$1.1M obligationsEnds Jun 30, 2024
THE NHLBI REQUIRES THE GENE THERAPY RESOURCE PROGRAM (GTRP) SUPPORT TRANSLATIONAL GENE THERAPY RESEARCH BY PROVIDING RESOURCES AND SERVICES FROM THREE CORE LABORATORIES: 1.)…Department of Health and Human Services$507.7K obligationsEnds Dec 18, 2023
EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. PERIOD OF PERFORMANCE…Department of Health and Human Services$2.3M obligationsEnds Jul 15, 2025
CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022Department of Health and Human Services$2.3M obligationsEnds Apr 28, 2025
EVALUATION OF POTENTIAL RESPIRATORY STIMULANT. TO4. PERIOD OF PERFORMANCE: MARCH 21, 2024 - MARCH 20, 2025.Department of Health and Human Services$140.8K obligationsEnds Apr 28, 2025
RESPIRATORY INTERACTION STUDIES IN RODENTS, ABILITY OF A TEST ARTICLE TO REVERSE THE RESPIRATORY DEPRESSANT EFFECTS OF OPIOIDS. TO5. PERIOD OF PERFORMANCE: MARCH 21, 2024 - MARCH…Department of Health and Human Services$211.1K obligationsEnds Apr 23, 2025
TASK ORDER 1 -TITLE: ARE REDUCTIONS IN BOE, BOPH, AND OTHER HEALTH RISK MARKERS PROPORTIONAL TO REDUCTIONS IN CIGARETTE SMOKING UPON SWITCHING TO ENDSDepartment of Health and Human Services$3.9M obligationsEnds Apr 18, 2025